
Releases
Valion Bio Secures Pentagon-Backed Protocol for Entolimod Testing
The Armed Forces Radiobiology Research Institute and the National Institute of Allergy and Infectious Diseases have finalized a rigorous survival efficacy protocol to test Valion Bio’s Entolimod, a lead candidate positioned as the first potential treatment for gastrointestinal acute radiation syndrome in an increasingly vital biodefense market.





















